Reaffirming revenue guidance, especially when it aligns with consensus estimates, tends to instill confidence in investors about the company's financial health and operational stability. For KPTI, maintaining its revenue outlook for 2024, particularly with a significant portion expected from XPOVIO sales in the U.S., suggests a positive outlook on its commercial activities and market demand for its product. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.